172 related articles for article (PubMed ID: 25156643)
1. Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic.
Duits FH; Prins ND; Lemstra AW; Pijnenburg YA; Bouwman FH; Teunissen CE; Scheltens P; van der Flier WM
Alzheimers Dement; 2015 May; 11(5):523-32. PubMed ID: 25156643
[TBL] [Abstract][Full Text] [Related]
2. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic impact of CSF biomarkers in a local hospital memory clinic.
Kester MI; Boelaarts L; Bouwman FH; Vogels RL; Groot ER; van Elk EJ; Blankenstein MA; van der Flier WM; Scheltens P
Dement Geriatr Cogn Disord; 2010; 29(6):491-7. PubMed ID: 20523047
[TBL] [Abstract][Full Text] [Related]
5. Preclinical AD predicts decline in memory and executive functions in subjective complaints.
van Harten AC; Smits LL; Teunissen CE; Visser PJ; Koene T; Blankenstein MA; Scheltens P; van der Flier WM
Neurology; 2013 Oct; 81(16):1409-16. PubMed ID: 24049134
[TBL] [Abstract][Full Text] [Related]
6. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
7. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
8. Impact of the 2008-2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM Study.
Gabelle A; Dumurgier J; Vercruysse O; Paquet C; Bombois S; Laplanche JL; Peoc'h K; Schraen S; Buée L; Pasquier F; Hugon J; Touchon J; Lehmann S
J Alzheimers Dis; 2013; 34(1):297-305. PubMed ID: 23186986
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
Parnetti L; Lanari A; Silvestrelli G; Saggese E; Reboldi P
Mech Ageing Dev; 2006 Feb; 127(2):129-32. PubMed ID: 16274728
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
12. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic.
Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P
Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519
[TBL] [Abstract][Full Text] [Related]
13. Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).
Seppälä TT; Louhija UM; Appelberg B; Herukka SK; Juva K
Am J Geriatr Psychiatry; 2014 Sep; 22(9):908-16. PubMed ID: 23597931
[TBL] [Abstract][Full Text] [Related]
14. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
Lewczuk P; Kamrowski-Kruck H; Peters O; Heuser I; Jessen F; Popp J; Bürger K; Hampel H; Frölich L; Wolf S; Prinz B; Jahn H; Luckhaus Ch; Perneczky R; Hüll M; Schröder J; Kessler H; Pantel J; Gertz HJ; Klafki HW; Kölsch H; Reulbach U; Esselmann H; Maler JM; Bibl M; Kornhuber J; Wiltfang J
Mol Psychiatry; 2010 Feb; 15(2):138-45. PubMed ID: 18663368
[TBL] [Abstract][Full Text] [Related]
15. A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers.
Spies PE; Claassen JA; Peer PG; Blankenstein MA; Teunissen CE; Scheltens P; van der Flier WM; Olde Rikkert MG; Verbeek MM
Alzheimers Dement; 2013 May; 9(3):262-8. PubMed ID: 23123231
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
Schmand B; Huizenga HM; van Gool WA
Psychol Med; 2010 Jan; 40(1):135-45. PubMed ID: 19863841
[TBL] [Abstract][Full Text] [Related]
17. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
19. Increased cerebrospinal fluid calpain activity and microparticle levels in Alzheimer's disease.
Laske C; Stellos K; Kempter I; Stransky E; Maetzler W; Fleming I; Randriamboavonjy V
Alzheimers Dement; 2015 May; 11(5):465-74. PubMed ID: 25200336
[TBL] [Abstract][Full Text] [Related]
20. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France.
Cognat E; Mouton Liger F; Troussière AC; Wallon D; Dumurgier J; Magnin E; Duron E; Gabelle A; Croisile B; de la Sayette V; Jager A; Blanc F; Bouaziz-Amar E; Miguet-Alfonsi C; Quillard M; Schraen S; Philippi N; Beaufils E; Pasquier F; Hannequin D; Robert P; Hugon J; Paquet C;
BMJ Open; 2019 May; 9(5):e026380. PubMed ID: 31152032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
